Full-Time
Clinical Affairs Specimen Operations Specialist
Associate
Posted on 8/21/2026
Abbott
10,001+ employees
Global healthcare company manufacturing medical devices
Compensation Overview
$50.7k - $101.3k/yr
No H1B Sponsorship
Madison, WI, USA
In Person
Travel between Madison locations and approximately 10% travel away from the work location may be required.
Bachelor's
 Biology & Biotech (1) |
|---|
Get referred to Abbott
See people who can refer or advise you
- A bachelor's degree in Business Administration, Engineering, Biology, or another field related to the essential duties of the position.
- At least 2 years of work experience in a project-focused environment.
- Proficiency with Microsoft Office suite programs.
- Authorization to work in the United States without sponsorship.
- Ability to perform the essential duties of the position with or without accommodation.
- Ability to maintain regular and reliable attendance and work the designated schedule, including nights and weekends as needed.
- Ability to lift up to 10 pounds for approximately 5% of a typical working day.
- Ability to work on a mobile device, tablet, or in front of a computer screen and perform typing for approximately 90% of a typical working day.
- Ability to grasp with both hands, pinch with the thumb and forefinger, turn with the hand or arm, and reach above shoulder height.
- Ability to comply with applicable personal protective equipment requirements.
- Ability to work on a computer and phone simultaneously and use a telephone through a headset.
- Ability and means to travel between Madison locations.
- Ability to travel 10% of working time away from the work location, potentially including overnight or weekend travel.
- Assist teams in dividing and organizing work into manageable packages and actionable schedules.
- Visualize and document processes.
- Assign tasks and confirm completion.
- Ensure on-time delivery of assigned goals.
- Lead defined small and medium-sized teams and components of large projects and programs.
- Schedule meetings and prepare agendas and minutes at the direction of stakeholders and leads.
- Liaise between internal and external stakeholders and Abbott Cancer Diagnostics team members.
- Keep relevant information organized and available to appropriate stakeholders and team members.
- Manage issues and action items and collaborate directly with team members to ensure completion.
- Coordinate and provide communication updates to key stakeholders, management, and team members.
- Maintain positive working relationships with internal parties and stakeholders.
- Lead and support process improvement initiatives within the clinical and regulatory affairs department.
- Analyze system user needs to identify efficiencies and gaps, assess cross-functional impact, and integrate stakeholder recommendations and needs to streamline process flow.
- Communicate efficiencies and gaps cross-functionally.
- Manage multiple priorities for stakeholders in a cross-functional matrix environment.
- Support and comply with the company's Quality Management System policies and procedures.
- Certified Associate in Project Management through the Project Management Institute.
- Experience with workflow design, including experience with Visio or other related programs.
- Strong understanding of Food and Drug Administration regulations and International Conference on Harmonisation Good Clinical Practice, including global regulations.
- Good understanding of clinical systems functionality and requirements.
Abbott develops and sells medical technologies and health solutions across cardiovascular care, diabetes management, diagnostics, nutrition, and neuromodulation. Cardiovascular devices help manage heart health; diabetes products enable glucose monitoring; diagnostic tests provide timely results; nutrition products support health; neuromodulation therapies target the nervous system to relieve pain or aid movement. It differentiates itself with a broad, integrated portfolio and a focus on accessibility and affordability of technologies worldwide. Its goal is to improve global health and well-being by delivering life-changing technologies that are accessible and affordable.
Company Size
10,001+
Company Stage
IPO
Headquarters
Lake Bluff, Illinois
Founded
1888
Get referred to Abbott
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 sales rose 13%; Abbott raised full-year adjusted EPS to $5.45-$5.60.
- Abbott and Google launched Lingo integration on August 11, 2026, expanding consumer reach.
- SimpleScreen CRC won FDA approval July 27, 2026; Abbott launches it this fall.
What critics are saying
- FDA's January 23, 2026 warning letter cited quality-system failures at Abbott Diabetes Care.
- February 4, 2026 Libre 3 recall linked to seven deaths and 860 serious injuries.
- Repeated Libre failures destroy Abbott's diabetes franchise; March 2026 stimulator litigation adds another legal front.
What makes Abbott unique
- Abbott combines FreeStyle Libre, diagnostics, nutrition, and devices across recurring-care categories.
- Cologuard, Cologuard Plus, and SimpleScreen give Abbott a screening franchise across stool and blood.
- Google Health integration makes Lingo a consumer-AI distribution channel, not just a sensor.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
401(k) Company Match
Flexible Work Hours
Remote Work Options
Paid Vacation
Paid Sick Leave
Paid Holidays
Professional Development Budget
Wellness Program
Growth & Insights and Company News
6 month growth
↑ 6%1 year growth
↑ 6%2 year growth
↑ 16%Abbott Laboratories reported strong fiscal Q2 2026 results, with sales rising 13% on a reported basis and 4.8% on a comparable basis, beating estimates and prompting the company to raise its annual profit forecast. The diagnostics segment was particularly strong, growing 42% to $3.09 billion, driven by its cancer diagnostics business following the Exact Sciences acquisition. Intuitive Surgical also exceeded expectations in Q2 2026, with revenue growing 19% to $2.89 billion and adjusted EPS of $2.80, beating forecasts by $0.30. The company placed 468 da Vinci units during the quarter, an 18% year-over-year increase, whilst maintaining a non-GAAP gross margin of 70.0%. The companies present contrasting investment cases: Abbott offers diversified healthcare portfolio resilience, whilst Intuitive Surgical relies on its robotic surgery ecosystem with recurring revenue comprising approximately 85% of total sales.
Medtech breaches keep hitting corporate IT, not devices - and that's a blind spot in hospital vendor risk. Abbott, Stryker, Intuitive, Medtronic and other medtech companies disclosed cyberattacks this year. None involved a device - and the pattern should reshape how hospitals assess vendor risk. By Carrie Pallardy Aug 17, 2026, 3:22 PM Seven medical technology companies disclosed cyberattacks in the first half of 2026, and not one involved a compromised device. Instead, attackers are opting for corporate IT - internal applications, billing systems, customer portals and, in one case, a third-party platform sitting two steps away from any hospital. "The Hollywood version of medical device cybersecurity is hacking the pacemaker, but the everyday reality is hacking the company that makes the pacemaker," said Daniel Bardenstein, CEO and co-founder of Manifest Cyber and Aspen Policy Academy fellow. And the pace is picking up. Health care providers remain a popular target, but attacks on health care businesses - pharmaceutical companies, billing companies and health care technology providers - jumped 35% in the first half of this year compared to the second half of 2025, according to Comparitech. Stryker, Abbott, Intuitive, Medtronic, UFP Technologies and iRhythm have all disclosed attacks this year, according to company statements. Nearly every disclosure carried the same reassurance - no products were impacted - which is true as far as it goes, but the systems attackers did reach are the ones that hold hospital and patient data and keep billing, orders and deliveries moving. Why medtech companies. Like other parts of the health care supply chain, medtech companies safeguard valuable data and provide services the industry can't operate without, which makes them attractive to financially motivated groups. One of the groups claiming an Abbott attack was ShinyHunters - and the cybersecurity information sharing nonprofit Health-ISAC recently warned that ShinyHunters is having increased success targeting medical technology companies, according to BleepingComputer. Jamie Singer, a senior managing director at FTI Consulting, told DHI that most attacks she has observed on medtech companies have some element of data access and extortion. "They're [attackers] trying to get paid, and when they don't, then they make it very miserable for the organization," she said. "Not all have the disruptive nature, but most that we're seeing certainly have the data theft piece." For other threat actors, disruption is the goal rather than a byproduct. "When you're talking about nation state actors, I do think there is a goal of disruption to critical infrastructure in the US," Singer said. The Handala claim on the Stryker attack fits that pattern. What it costs hospitals. Medtech companies sit inside a tightly interconnected health care ecosystem, and the impact of an attack rarely stays inside the company's walls. "If a hospital gets breached through a medical device or otherwise, not only do those medical devices not work but the whole system may not work," said Sean Kelly, MD, chief medical officer at Imprivata, a digital identity security company, and a practicing ER physician. Kelly has received patients diverted from hospitals disrupted by cyberattacks. "When that happens, patients arrive and you don't have access to their data," he said. "We're starting over trying to understand what their meds are, what their problems are, how to treat them." The result, according to Kelly: care delays, higher risk of errors and increased costs. Regulation mirrors the blind spot. Regulators have taken steps, though largely on the side of the equation attackers are avoiding. The FDA's premarket cybersecurity requirements focus on the device itself, while HHS's Cybersecurity Performance Goals for the health care and public health sector, released in 2024, remain voluntary. "There has been work [done] to identify: how do we establish a minimum, and how do we do the basics better across the sector?" Bardenstein said. "I think there needs to be an increase in what is mandatory and not what is aspirational." "It means that despite the millions of dollars that security leaders at the medtech companies are currently spending, the tooling or the processes they have aren't enough," he added. For hospitals, the same question applies to their own side of the relationship. Most vendor risk assessments still focus on the device - whether it's patched, segmented and hardened against attack. This year's attacks point somewhere else entirely: to the security of the company that makes the pacemaker. Carrie Pallardy, a Chicago-based freelance writer and editor, began her career covering healthcare more than a decade ago. Her work has taken into many different industries, but covering healthcare delivery remains a constant focus. She can be reached at [email protected] or on LinkedIn. Show your support. Subscribe. Enter your information below
Can Abbott Laboratories (abt)'s Lingo partnership with Alphabet (GOOG) unlock a new era of ai-powered health? Published on August 14, 2026 at 9:05 pm by laiba immad in hedge funds, news. On August 11, medtech leader Abbott Laboratories (NYSE:ABT) and tech behemoth Alphabet Inc. (NASDAQ:GOOG) announced a multi-year partnership to unite continuous glucose monitoring with consumer AI. The collaboration embeds data from Abbott's non-prescription Lingo biowearable directly into the Google Health app, combining real-time metabolic insights with Google's AI Health Coach to deliver personalized habit recommendations around nutrition, sleep, and recovery. While the partnership highlights how health tech is blurring traditional industry boundaries, Abbott and Google operate in vastly different financial realms. Comparing a defensive healthcare dividend aristocrat with a hyper-growth AI heavyweight requires evaluating how each leverages its financial engine to power its next growth phase. Financial heavyweights: Abbott Laboratories (NYSE:ABT) $111.26-0.01%'s steady expansion vs. Alphabet Inc. (NASDAQ:GOOG)'s AI blitz. Abbott reported strong Q2 2026 results, generating $12.59 billion in sales, up 13.0% reported (4.8% on a comparable basis). Adjusted diluted EPS hit $1.31, beating expectations and prompting management to raise full-year EPS guidance to $5.45-$5.60. Abbott's continuous growth is underpinned by its Medical Devices division, particularly Diabetes Care, which surged 10.5% reported, and the integration of Exact Sciences in its Diagnostics segment. Returning $2.1 billion to shareholders in Q1 via dividends and buybacks, Abbott exemplifies high-margin, resilient cash flow. Alphabet, meanwhile, delivered explosive Q2 2026 numbers driven by AI demand. Revenue spiked 24% year-over-year to $119.8 billion, while Google Cloud revenue skyrocketed 82% on the back of Gemini model adoption. Search revenue grew 17%, proving that generative AI integrations are enhancing rather than cannibalizing its ad engine. With massive cash reserves and an accelerating Cloud backlog ($514 billion), Alphabet commands unmatched scale and growth velocity compared to any healthcare stock. Bull and bear cases. Abbott's bull case is supported by strong organic momentum in its medical devices business, particularly high-margin continuous glucose monitoring products such as Libre and Lingo. Accretive acquisitions such as Exact Sciences further strengthen Abbott's position in preventive metabolic health and oncology diagnostics, potentially allowing the company to capture significant market share in these expanding markets. However, the bear case centers on persistent weakness in its Nutrition business, which declined 3.1% in Q2, as well as pricing pressure in emerging markets. If medical device growth slows, these pressures could weigh on overall margins. Alphabet's bull case rests on its end-to-end AI infrastructure, including TPUs, Gemini models, and enterprise platforms, which are increasingly translating into revenue growth. Rapid expansion in Google Cloud, combined with Search's continued dominance, provides multiple engines for sustained growth. On the downside, Alphabet's aggressive capital spending on AI data centers could pressure free cash flow margins, particularly if AI monetization fails to keep pace with investment. Ongoing regulatory and antitrust scrutiny also presents a potential risk to the company's long-term business model. Insider Monkey's hedge fund data analysis. Insider Monkey's hedge fund database shows divergent institutional sentiment leading into the second quarter. Abbott Laboratories (NYSE:ABT) saw an uptick in hedge fund interest, with 73 funds holding shares in Q1 2026, up from 71 in Q4 2025. Major holders include Diamond Hill Capital (Ric Dillon) holding 4.93 million shares valued at $447.9 million despite a 9% trim, and Locust Wood Capital Advisers (Stephen J. Errico), which expanded its stake by 59% to 1.72 million shares ($156.2 million). Conversely, Alphabet Inc. (NASDAQ:GOOG) saw a minor decline in fund count, dropping to 201 hedge fund holdings in Q1 2026 from 203 in Q4 2025. Quaker Capital Investments (Mark G. Schoeppner) held 17,110 shares valued at $4.9 million, reflecting minor repositioning among institutional investors despite Alphabet's massive secular tailwinds. Conclusion: what investors should watch next. Comparing Abbott Laboratories and Alphabet Inc. is less about choosing between balance sheets and more about asset allocation. Abbott offers investors low-beta healthcare stability, reliable dividend expansion, and compounding medtech growth. Alphabet offers high-beta exposure to the modern AI revolution with unmatched top-line expansion. Going forward, investors should watch how effectively the Lingo-Google Health integration drives user retention for Abbott's biowearable ecosystem, and whether Google can successfully translate consumer health engagement into higher ecosystem lock-in and Google Cloud enterprise wins in healthcare. While we acknowledge the risk and potential of ABT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABT and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Abbott, Google to combine glucose data with AI coaching. The multiyear partnership will connect Abbott's over-the-counter Lingo sensor and the Google Health app. Published Aug. 12, 2026 Dive brief: * Abbott and Google plan to pair Abbott's over-the-counter glucose sensor with Google's artificial intelligence and consumer technology, the companies said Tuesday. * The multiyear partnership is focused on making metabolic insights from Abbott's device easier to use, helping people proactively manage their health. * The two companies plan to launch a large study that could inform Google's AI health coaching and future features for Abbott's Lingo sensor. Abbott did not disclose how many people they plan to enroll in the study. Dive insight: Abbott plans to roll out Lingo integrations with the Google Health app later this year. Abbott's over-the-counter glucose sensor, which debuted in the U.S. in 2024, provides readings for adults not taking insulin to help them understand how factors such as diet and exercise affect blood sugar levels. Google's Health app is built on its 2021 acquisition of Fitbit for $2.1 billion. Abbott and Google said their partnership is intended to help people take more informed actions to slow the progression of metabolic health conditions. Abbott will connect its glucose insights into Google Health to help people understand their body's response to daily habits. For people who have a Google Health premium subscription, Google's AI-powered health coach will use this data to provide recommendations to help people build healthier habits. The companies said they plan to conduct a large, real-world metabolic health study integrating continuous glucose, wearable, laboratory and survey data to understand the connections between activity, sleep, well-being and metabolic health. The results could inform more personalized guidance and help the companies improve their products. The collaboration comes as other diabetes tech firms are testing digital health partnerships and the use of AI. Competitor Dexcom is participating in a Food and Drug Administration pilot program where it will test an AI-enabled glucose health program to help people improve glycemic control and lower blood sugar levels.
Abbott and Google Health have announced a multi-year partnership combining glucose monitoring with artificial intelligence to transform personal health management. The collaboration will integrate data from Abbott's Lingo continuous glucose monitor into the Google Health app, where AI-powered coaching will provide personalized recommendations on nutrition, activity, sleep and stress. The partnership includes a large-scale research study examining connections between glucose levels, wearable data and metabolic health. Lingo, Abbott's over-the-counter glucose monitor, targets adults not using insulin who want to understand how daily habits affect their glucose levels. Over 115 million American adults have prediabetes, with approximately 80% unaware of their condition. The companies aim to help people take proactive action before health challenges become chronic conditions. Lingo integrations will roll out in the Google Health app later this year.